Thus, CRISPR/Cas9-mediated knock-down of NGAL expression in N2-type neutrophils inhibits MET in metastatic breast cancer cells, thereby strongly reducing lung metastasis formation [65]. The gene discussed is LCN2; the disease is breast carcinoma.